New York Attorney General Eric Schneiderman announced Tuesday that his
office has launched an antitrust investigation of Mylan Pharmaceuticals'
EpiPen contracts with school districts.
Schneiderman's office said during a
preliminary review that the company may have placed "potentially
anti-competitive terms into its EpiPen sales contracts with numerous
local school systems,"
according to a release.
"No child's life should be put at risk because
a parent, school, or health care provider cannot afford a simple,
life-saving device because of a drug-maker's anti-competitive
practices," Schneiderman said in the release.
A price increase from $57 per pen in 2007 to about $500 per pen today has caused nationwide outrage, with
four U.S. senators grilling Mylan at a hearing last month.
The pens are used in an emergencies for food allergies and there are no generic equivalents.
"If Mylan engaged in anti-competitive business
practices, or violated antitrust laws with the intent and effect of
limiting lower cost competition, we will hold them accountable,"
Schneiderman said. "Allergy sufferers have enough concerns to worry
about — the availability of life-saving medical treatment should not be
one of them. I will bring the full resources of my office to this
critical investigation."
The announcement came on the same day U.S. Sens.
Richard Blumenthal, D-Conn., and
Amy Klobuchar,
D-Minn., asked the Federal Trade Commission to investigate whether
Mylan violated federal antitrust laws. These two senators, as well as
Sen.
Chuck Grassley, R-Iowa, and Sen.
Bernie Sanders, D-Vt., have questioned the increases.
"Some of these schools were required to sign a
contract agreeing not to purchase any products from Mylan's competitors
for a period of 12 months — conduct that can violate the antitrust laws
when taken by a monopolist," Blumental
said in a statement.
On Friday, Democratic presidential nominee
Hillary Clinton
released a plan she said will prohibit pharmaceutical companies from
arbitrarily hiking the price for potentially life-saving medications.
A Mylan spokeswoman defended the practice of
giving 700,000 free EpiPens to 65,000 schools, pointing out there are no
purchase restrictions.
"The program continues to adhere to all
applicable laws and regulations. There are no purchase requirements for
participation in the program, nor have there ever been to receive free
EpiPen Auto-Injectors," she said. "Previously, schools who wished to
purchase EpiPen Auto-Injectors beyond those they were eligible to
receive free under the program could elect to do so at a certain
discount level with a limited purchase restriction, but such restriction
no longer remains."
The company
recently announced
new programs to expand "already existing programs in recognition of
those patients who are facing the burden of higher out-of-pocket costs."
The company reduced the patient cost of pens
through the use of a savings card, which will cover up to $300 for a
two-pack. Mylan also is doubling the eligibility for its patient
assistance program, which will eliminate out-of-pocket costs for
uninsured and under-insured patients and families.
Comments
Post a Comment